Open Label Extension Study of Bifeprunox

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 30, 2006

Study Completion Date

October 31, 2007

Conditions
Schizophrenia
Interventions
DRUG

Bifeprunox

Trial Locations (83)

10312

Staten Island

11203

Brooklyn

14215

Buffalo

14624

Rochester

15108

Pittsburgh

18301

East Stroudsburg

19149

Philadelphia

19401

Norristown

19406

Jenkintown

20877

Gaithersburg

21286

Towson

27509

Butner

27707

Durham

28557

Morehead City

30060

Marietta

30307

Atlanta

30308

Atlanta

32207

Jacksonville

32256

Jacksonville

32763

Orange City

33016

Hialeah

33161

North Miami

33319

Fort Lauderdale

33426

Boynton Beach

33613

Tampa

33711

St. Petersburg

38018

Cordova

38105

Memphis

38157

Memphis

39232

Flowood

44109

Cleveland

44122

Beachwood

46202

Indiannapolis

60077

Joliet

60194

Hoffman Estates

60540

Naperville

60631

Chicago

63104

St Louis

63110

St Louis

63118

St Louis

63128

St Louis

69101

North Platte

70601

Lake Charles

72201

Little Rock

72211

Little Rock

73139

Oklahoma City

75062

Irving

75115

DeSoto

77007

Houston

78229

San Antonio

78756

Austin

83814

Coevr d'Alene

90505

Torrance

90620

Buena Park

90703

Cerritos

90723

Paramount

91206

Glendale

91770

Rosemead

91942

La Mesa

91950

National City

92025

Escondido

92056

Oceanside

92108

San Diego

92123

San Diego

92126

San Diego

92363

Costa Mesa

92627

Costa Mesa

92648

Huntington Beach

92701

Santa Ana

92705

Santa Ana

92802

Anaheim

92804

Anaheim

92805

Anaheim

92845

Garden Grove

95823

Sacramento

98033

Kirkland

06030

Farmington

06106

Hartford

06320

New London

01201

Pittsfield

01605

Worcester

08002

Cherry Hill

08021

Clementon

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00366171 - Open Label Extension Study of Bifeprunox | Biotech Hunter | Biotech Hunter